Investor Centre

Clinicians to Speak About Pharmaxis Programs

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) will host R&D showcase webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs will be followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers.

Pharmaxis drug PXS-5505 targeting several cancers:

Date & time: 29 March 2022 at 11.00am (AEDT)

Speakers:

• Myelofibrosis - Dr Gabriela Hobbs, Assistant Professor, Medicine, Harvard Medical School & Clinical Director, Leukaemia, Massachusetts General Hospital
• Hepatocellular carcinoma - Dr Paul Burchard, University of Rochester
• Pancreatic cancer - Dr Tom Cox, A/Prof School of Clinical Medicine, UNSW Sydney, Laboratory Head - Matrix and Metastasis, Garvan Institute of Medical Research

To register for this event please use the following link: https://zoom.us/webinar/register/WN_B8Te020aTUqyb2A3H93saA

 Pharmaxis drug PXS-6302 targeting scarring:

Date & time: 31 March 2022 at 11.00am (AEDT)

Speakers:

• The science of scarring and potential for LOX inhibition - Dr. Mark Fear, Senior Research Fellow University of Western Australia
• Clinical applications for LOX inhibition, unmet need and clinical development strategy - Professor Fiona Wood AM, Director of the Burn Injury Research Unit University of Western Australia

To register for this event please use the following link: https://zoom.us/webinar/register/WN_66zxZbVsRm-GCocT8_NiAQ

 The webinars are free to attend and a recording of the events will be made available on the Pharmaxis website. 

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that it has initiated the first of 5 new trial sites in Taiwan as it progresses the phase 2 clinical trial of its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis. These latest centres join 11 active sites across Australia and South Korea with a further 4 centres in the US expected to come on stream in coming months.  

Pharmaxis CEO Gary Phillips said, “This planned initiation of new trial sites in Taiwan will bring the total number of active sites to 16.  The study is making pleasing progress as it builds to a recruitment target of 24 patients. This latest expansion of sites is part of a focused effort by the company to bring patients into the trial and deliver results by the year end.”  

Mr Phillips added, “We know from the earlier dose escalation study that PXS-5505 will fully block the LOX enzymes that play a fundamental part in the bone marrow fibrosis that characterises myelofibrosis, giving hope that the drug can modify the course of the disease.  The good tolerability profile, which is a key differentiator from current standard of care, was first demonstrated in healthy volunteers and then backed up by myelofibrosis patients on 1 month of therapy in the dose escalation study.  I am pleased to report that we now have experience with patients who have had 3 or more months of therapy on PXS-5505 and that the good tolerability profile is being maintained.”